(Q47132312)

8 January 2018

case report

0 references

title

Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator (English)

1 reference

8 January 2018

0 references

Fabrizio Cantini

1

1 reference

8 January 2018

Laura Niccoli

2

1 reference

8 January 2018

Carlotta Nannini

3

1 reference

8 January 2018

Emanuele Cassarà

4

1 reference

8 January 2018

Olga Kaloudi

5

1 reference

8 January 2018

publication date

25 October 2017

1 reference

8 January 2018

European journal of rheumatology

published in

1 reference

8 January 2018

volume

4

1 reference

8 January 2018

issue

4

1 reference

8 January 2018

page(s)

288-290

1 reference

8 January 2018

Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Efficacy of Anti-TNFα in Severe and Refractory Neuro-Behcet Disease: An Observational Study

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used a

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Therapy of ocular Behçet disease

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.

23 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5741345

Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study

15 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29308287

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29308287

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.5152/EURJRHEUM.2017.16112

1 reference

3 February 2018

PMCID

5741345

1 reference

8 January 2018

PubMed ID

29308287

1 reference

3 February 2018